|RxNews Recap for Thursday 01-07-10|
|By Mary Davila|
|Thursday, 07 January 2010 22:06|
Biotech investors interested in seeing more details about these companies and a full list of their related stories can do so by typing the stock ticker symbol into the Stock Quotes box on the right side of the page.
AdvanSource Biomaterials Corporation (NYSE Amex: ASB), a leading developer of advanced polymer materials for a broad range of medical devices, today announced its commercial expansion through the addition of Debbie Hauser as its independent western regional sales engineer.
Advanced Cell Technology, Inc. (OTCBB:ACTC), a biotechnology company applying cellular technology in the field of regenerative medicine, announced today that it will present at the OneMedForum 2010 Emerging Company Finance Conference on Tuesday, January 12th at the Sir Francis Drake Hotel in San Francisco, CA in the Windsor & Renaissance Rooms.
Biovest International, Inc. (Other OTC: BVTI) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to BiovaxID®, Biovest’s personalized lymphoma vaccine.
Genzyme Corporation (NASDAQ: GENZ) and San-Diego based institutional investor Relational Investors LLC announced today that they have entered into a mutual cooperation agreement.
Law Offices of Howard G. Smith announces that it is investigating potential claims against Hemispherx Biopharma, Inc. (“Hemispherx” or the “Company”) (AMEX:HEB) concerning possible breaches of fiduciary duty and/or other violations of law by the Hemispherx board of directors, related to public statements issued by Hemispherx concerning the status of the Company’s New Drug Application ("NDA") filed with the U.S. Food and Drug Administration ("FDA") for marketing approval for Ampligen – an experimental drug undergoing clinical development for the treatment of chronic fatigue syndrome.
Inovio Biomedical Corporation (NYSE Amex:INO), a leader in DNA vaccine design, development and delivery, announced today that Dr. J. Joseph Kim will present at the OneMedForum investor conference on Wednesday, January 13th at 1:45 p.m. at the Sir Francis Drake Hotel in San Francisco.
Merck & Co., Inc. (NYSE: MRK) will hold its fourth-quarter 2009 sales and earnings conference call with institutional investors and analysts beginning at 8 a.m. EST on Tuesday, Feb. 16.
Pall Corporation (NYSE: PLL), a global leader in filtration, separation and purification, announces the launch of 5 mL PRC prepacked chromatography columns to deliver faster and more consistent protein purification processing.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT) reports on its 2009 clinical and corporate accomplishments, as well as 2010 clinical development plans, in a letter to shareholders from Craig Dees, Ph.D., CEO of Provectus.
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that it has entered into two definitive agreements with AstraZeneca to settle patent litigation regarding Teva’s U.S. generic versions of AstraZeneca’s Prilosec® (omeprazole) and Nexium® (esomeprazole), including all claims for patent infringement and damages.
As required under the indenture covering Apogent Technologies Inc. Floating Rate Convertible Senior Debentures due 2033 (CUSIP No. 03760AAK7), Thermo Fisher Scientific Inc. (NYSE: TMO) is providing public notice to the holders of these bonds that they have the right to convert the debentures.
During its investor meeting today, Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) presented an updated strategy, highlighting key opportunities for growth and announcing its long-term goals of reaching revenues of $31 billion and non-GAAP net income of $6.8 billion, or 22% of revenues, by 2015.